Designed for specialist prescribers and clinicians, this advanced module evaluates the evidence base for medical cannabis across a spectrum of neurological disorders.
You will examine the role of the Endocannabinoid System (ECS) in modulating neural activity and critical data – ranging from rigorous RCTs for licensed indications (Dravet and Lennox-Gastaut syndromes, MS spasticity) to emerging Real-World Data (RWD) for off-label use in movement and sleep disorders.
By the end of this course you will be able to:
The Endocannabinoid System in Neurology
Licensed vs. Unlicensed Indications
The “Unmet Need” in Neurology
Drug-Resistant Epilepsy: The Challenge
Mechanisms: Modulating Excitability
Evidence Base: Epidyolex® & CBD
Safety: The CBD-Clobazam Interaction
Parkinson’s & Huntington’s Disease
Evidence Review: Motor vs. Non-Motor
Managing Symptom Clusters
Limitations of Current Research
The Role of the ECS in Sleep
Evidence Review: RCTs vs. Real-World Data
Dosing Strategies (Biphasic Effects)
Safety & Tolerance
Pathophysiology & Spasticity
Evidence Base: Sativex® & Cannabis
Managing Associated Symptoms (Pain/Bladder)
Safety & Nabiximols Specifics
Formulation Selection (Dexterity & Swallowing)
Titration: Epidyolex® & Sativex®
Unlicensed Dosing Protocols
Monitoring, Safety & Driving
Alongside this course, the Foundations of Medical Cannabis pathway includes additional courses that expand on history, biology, and clinical practice. Each is short, [[CPD_ACCREDITED_COMMA]]and designed to build confidence step by step.